ITGAM and acute myeloid leukemia: CD34+, CD34+CD38−, or CD123+ cells were considerably more resistant to ISC-4 (Figure S2A), and indeed, minimal effects were seen on CD11b+ myeloid cells with ISC-4 up to 10 μM, suggesting a potential therapeutic window for the selective targeting of AML cells (Figure S2B).